Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia, according to Roche. Data from multiple studies have ...
VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...
The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie ...
(RTTNews) - The European Commission has approved Venclyxto or venetoclax in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly ...
In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall ...
Patients with certain forms of chronic lymphocytic leukaemia are unlikely to get access to AbbVie's Venclyxto on the NHS after cost regulators rejected funding for the drug. Patients with certain ...
VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...
(RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or ...
The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who ...
"Results from the CLL14 and MURANO studies demonstrate the long-term benefits of fixed-duration venetoclax combinations for patients living with CLL," said Mariana Cota Stirner, M.D., Ph.D., vice ...
VENCLYXTO ® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results